Introduction
============

Neuroblastoma, one the most common solid cancer in children, is characterized by various clinical phenotypes [@B1]. It accounts for about 7% of all cancer types in children under 15 years of age [@B2], [@B3]. The prevalence of neuroblastoma is higher in the United States [@B4] than that in China [@B5] (8-14 cases per million versus about 7.7 per million). Neuroblastoma can be categorized into three different groups, low-risk, intermediate-risk, and high-risk groups. A large proportion of the affected patients have a favorable prognosis, as they bear localized benign tumors that can regress spontaneously [@B6]. The survival rate for low-risk patients is generally greater than 95%, no matter treated with minimal chemotherapy or not. Patients with intermediate-risk neuroblastoma constitute about 15% of all neuroblastoma patients, and their survival rate is larger than 80% after multimodal therapy. Moreover, nearly 50% of patients are classified as high-risk neuroblastoma, with survival rate approximately less than 35% even after\` receiving comprehensive treatments [@B7], [@B8]. Such poor prognosis might be attributed to the widespread dissemination of tumor to bone and bone marrow at the time of diagnosis.

By now, the etiology of familial neuroblastoma is mainly attributed to the *ALK* [@B9], [@B10] and *PHOX2B* [@B11], [@B12] gene mutations. However, familial neuroblastoma only accounts for 1% of all neuroblastoma cases [@B13]. The explicit causes of most common sporadic neuroblastoma still remain obscure. Previous studies have paid attention to the role of environmental risk factors in influencing susceptibility to neuroblastoma [@B14], [@B15]. However, environmental etiology alone cannot explain the fact that only a small portion of children finally developed neuroblastoma after parental exposure to risk environmental factors [@B16]. Mounting evidence has suggested that genetic factors and gene-environmental interactions might influence the susceptibility to neuroblastoma [@B17], [@B18].

Early genome-wide association studies (GWASs) of neuroblastoma have identified a number of neuroblastoma susceptibility loci in the genes including *BARD1* [@B19], *DUSP12* [@B20], *DDX4* [@B20], *HSD17B12* [@B20], *IL31RA* [@B20]*, LIN28B* [@B21], *HACE1* [@B21], and *LMO1* [@B22]. Moreover, several single nucleotide polymorphisms (SNPs) in lncRNA also contributed to the susceptibility to neuroblastoma and other cancers [@B23], [@B24]. However, these gene loci only account for a small fraction of neuroblastoma heritability. Some potential functional gene loci might be ruled out as a result of the introduction of the multiple testing corrections in GWAS [@B25]. To discover more hidden true-positive loci, a variety of novel methods have been presented. The methods include but not limit to: adopting gene- or pathway-based approaches, using larger GWAS samples, replicating previously reported GWAS signals in a larger cohort, conducting a meta-analysis of GWAS datasets, and performing imputation and epistasis analysis [@B26]. For instance, using larger GWAS samples, rare variants of *TP53* were found to be associated with neuroblastoma predisposition [@B27].

In a previous proteomic study on differentiated neuroblastoma cell line, Capasso et al. [@B28] found that eight proteins were differentially expressed during neuroblastoma differentiation. To discover more variants predisposing to neuroblastoma, Capasso et al. [@B29] further investigated whether the genes encoding these eight proteins were related to neuroblastoma development. Using the discovery set (2,101 patients and 4,202 control subjects) and the replication set (459 cases and 809 controls), they successfully identified three common neuroblastoma predisposing variants in the *neurofilament light* (*NEFL*) gene (rs11994014 G\>A, rs2979704 T\>C, rs1059111 A\>T).

Here, we tested the association between the three putative SNPs in *NEFL* gene and neuroblastoma risk in a two-center, case-control study in Chinese population. The aim of our study was to reveal the contribution of these SNPs to the neuroblastoma susceptibility in Chinese children.

Materials and methods
=====================

Study subjects
--------------

This study consisted of two populations, one including 256 cases and 531 controls from Guangdong province, and the other including 118 cases and 281 controls from Henan province (**Supplemental Table [1](#SM0){ref-type="supplementary-material"}**) [@B30]. The selection details and criteria of the subjects were provided in our previously published articles [@B31]-[@B36]. At recruitment, informed written consent was obtained from all participants or their guardians. The study protocols were approved by the Institutional Review Boards of Guangzhou Women and Children\'s Medical Center and the First Affiliated Hospital of Zhengzhou University.

SNP selection and genotyping
----------------------------

Three SNPs (rs11994014 G\>A, rs2979704 T\>C, rs1059111 A\>T) in the*NEFL* gene by Capasso et al. [@B29] were selected. Genomic DNA was mainly purified from venous blood collected from the subjects, using a TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd., Beijing, China). Genotyping was performed using TaqMan real-time PCR by standard methods, with details reported elsewhere [@B37]-[@B39]. For quality control, we randomly selected approximately 10% of the samples to perform duplicate analyses. 100% concordance rate was observed for each SNP among duplicate sets.

Statistical analysis
--------------------

Deviation from Hardy-Weinberg equilibrium (HWE) for each SNP was assessed in the control subjects, using the goodness-of-fit χ^2^ test. The chi-squared test was employed to evaluate differences in the demographic variables and allele frequencies between the cases and controls. Odds ratios and corresponding 95% confidence intervals were calculated to determine the relative cancer risk, adjusting for age and gender. A two-sided *P* value \< 0.05 was set as the statistical significance level. All statistical analyses were conducted using SAS statistical package, version 9.1 (SAS Institute, Cary, NC).

Results
=======

Association between NEFL gene polymorphisms and neuroblastoma susceptibility
----------------------------------------------------------------------------

Genotyping were successfully conducted in the Guangdong population (255 cases and 531 controls) and Henan population (118 cases and 281 controls). The genotype frequencies and association results of these three *NEFL* gene polymorphisms (rs11994014 G\>A, rs2979704 T\>C, and rs1059111 A\>T) were presented for Guangdong, Henan, and combined population separately in **Table [1](#T1){ref-type="table"}**. All of these three polymorphisms were agreed with HWE (*P*=0.513 for rs11994014 G\>A, *P*=0.498 for rs2979704 T\>C, and *P*=0.535 for rs1059111 A\>T in the controls of combined population). No significant association between these three polymorphisms and neuroblastoma risk was observed in either study population. We then validated such association in the combined population, aiming to obtain a robust conclusion. Likely, no association were found between these three polymorphisms and neuroblastoma risk (**Table [1](#T1){ref-type="table"}**).

Stratification analysis for the association between NEFL gene polymorphisms and neuroblastoma susceptibility for combined subjects
----------------------------------------------------------------------------------------------------------------------------------

Stratified analysis was also performed in the combined population by age, gender, sites of origin, and clinical stages. Consistently, we found no significant associations for all these three polymorphisms (**Table [2](#T2){ref-type="table"}**).

Discussion
==========

Herein, we investigated the association of *NEFL* gene polymorphisms with neuroblastoma risk in Chinese population. To the best of our knowledge, this is the first study to replicate the previously reported associations between *NEFL* gene polymorphisms and neuroblastoma risk in a two-center case-control study of Chinese children.

*NEFL* gene is located at chromosome 8p21.2. This gene encodes the light subunit of neurofilaments, which play an important role in maintaining normal function of nerve cells [@B40], [@B41]. More than 10 mutations in the *NEFL* gene are found to be associated with Charcot-Marie-Tooth disease types 2, or distal nerve demyelination [@B42]. In addition to the definite role of *NEFL* gene in neuron disease, *NEFL* gene also has been implicated in cancer initiation and progression. First, the chromosome 8p21 is enriched for loss of heterozygosity (LOH), which was involved in various cancers, including breast cancer [@B43], [@B44], lung cancer [@B45], prostate cancer [@B46], head and neck cancer [@B47]. It was reported that more than 40% of head and neck cancer patients harbored LOH at the *NEFL* locus. Second, several functional molecular targets related to cancer-associated pathways have been shown to interact with *NEFL* gene [@B48]. Furthermore, *NEFL* could also alter the cancer cell resistance to chemotherapy. Previous study has pointed out that restoring expression of *NEFL* in head and neck cancer cell lines could increase sensitivity of the cells to the cisplatin [@B48]. Last, aberrant expression and methylation of *NEFL* gene was detected in several cancers [@B49]-[@B51].

Given the common implication of *NEFL* in carcinogenesis as well as the relative paucity of investigation into its role in neuroblastoma risk, we were motivated to explore the association between the three *NEFL* polymorphisms and neuroblastoma risk in a two-center case-control study of Chinese children. Unexpectedly, both overall analysis and stratified analysis indicated that there was no significant association of these studied *NEFL* polymorphisms with neuroblastoma risk in the study populations. Such negative association results might be ascribed to the following possible reasons. First, relatively small sample size might result in inadequate power to detect moderate effects. Second, most of the common SNPs only have weak effects on cancer risk [@B24], [@B52]. Thus, effects of*NEFL* polymorphisms might be overridden by environmental factors or other genetic variations. Third, lack of association between these three *NEFL* polymorphisms and neuroblastoma in Chinese children may be attributed to ethnic differences in allele frequencies of the SNPs (**Supplemental Table [2](#SM0){ref-type="supplementary-material"}**).

Although this study has some merits, limitations are inevitable. First, inherent bias could not be avoided in this case-control study, since all participants were enrolled from hospitals. Second, statistical power might be limited due to the moderate sample size. It is challenging to recruit more cases, due to the relatively low morbidity rate of neuroblastoma in China. Third, we only replicated three SNPs in *NEFL* gene in this study. There are other potentially functional SNPs that might modify neuroblastoma susceptibility. Thus, more SNPs are needed to be explored in the future. Fourth, details on environmental factors, including dietary intake, living environment, and parental exposures, were not accessible, which disables us to analyze gene-environmental interaction. Fifth, though this is a two-center study, all the subjects were unrelated Chinese Han ethnicity. It should be cautious to extrapolate the results to other ethnic groups.

In all, we for the first time replicated the association between the *NEFL* gene polymorphisms and neuroblastoma risk using two independent populations in China. No significant association with neuroblastoma risk was detected. More epidemiological studies in different ethnic group are warranted before fully ascertaining the contribution of the *NEFL* gene polymorphisms to neuroblastoma susceptibility.

Supplementary Material {#SM0}
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Association between *NEFL* gene polymorphisms and neuroblastoma susceptibility

  Genotype                                            Guangdong province   Henan province   Combined subjects                                                                                                                 
  --------------------------------------------------- -------------------- ---------------- ------------------- ------- ------------- ------------- ------------------ ------- ------------- ------------- ------------------ -------
  rs11994014 G\>A (HWE=0.513 for combined subjects)                                                                                                                                                                           
  GG                                                  83 (32.55)           186 (35.03)      1.00                        47 (39.83)    115 (40.93)   1.00                       130 (34.85)   301 (37.07)   1.00               
  AG                                                  127 (49.80)          267 (50.28)      1.06 (0.76-1.48)    0.747   60 (50.85)    127 (45.20)   1.13 (0.72-1.79)   0.595   187 (50.13)   394 (48.52)   1.10 (0.84-1.44)   0.496
  AA                                                  45 (17.65)           78 (14.69)       1.28 (0.81-2.00)    0.287   11 (9.32)     39 (13.88)    0.70 (0.33-1.48)   0.351   56 (15.01)    117 (14.41)   1.11 (0.76-1.62)   0.597
  Additive                                                                                  1.12 (0.90-1.39)    0.324                               0.92 (0.67-1.28)   0.632                               1.06 (0.89-1.27)   0.510
  Dominant                                            172 (67.45)          345 (64.97)      1.11 (0.81-1.52)    0.533   71 (60.17)    166 (59.07)   1.03 (0.66-1.60)   0.890   243 (65.15)   511 (62.93)   1.10 (0.85-1.42)   0.465
  Recessive                                           210 (82.35)          453 (85.31)      1.24 (0.83-1.85)    0.302   107 (90.68)   242 (86.12)   0.65 (0.32-1.33)   0.240   317 (84.99)   695 (85.59)   1.05 (0.74-1.48)   0.784
  rs2979704 T\>C (HWE=0.498 for combined subjects)                                                                                                                                                                            
  TT                                                  83 (32.55)           184 (34.65)      1.00                        48 (40.68)    115 (40.93)   1.00                       131 (35.12)   299 (36.82)   1.00               
  CT                                                  126 (49.41)          268 (50.47)      1.04 (0.74-1.45)    0.835   60 (50.85)    127 (45.20)   1.11 (0.70-1.75)   0.670   186 (49.87)   395 (48.65)   1.07 (0.82-1.41)   0.602
  CC                                                  46 (18.04)           79 (14.88)       1.28 (0.82-2.00)    0.286   10 (8.47)     39 (13.88)    0.62 (0.29-1.34)   0.225   56 (15.01)    118 (14.53)   1.08 (0.74-1.58)   0.680
  Additive                                                                                  1.11 (0.89-1.39)    0.338                               0.89 (0.64-1.23)   0.465                               1.05 (0.88-1.26)   0.609
  Dominant                                            172 (67.45)          347 (65.35)      1.09 (0.79-1.50)    0.592   70 (59.32)    166 (59.07)   0.99 (0.64-1.54)   0.968   242 (64.88)   513 (63.18)   1.08 (0.83-1.39)   0.574
  Recessive                                           209 (81.96)          452 (85.12)      1.25 (0.84-1.86)    0.275   108 (91.53)   242 (86.12)   0.59 (0.28-1.22)   0.155   317 (84.99)   694 (85.47)   1.04 (0.74-1.47)   0.827
  rs1059111 A\>T (HWE=0.535 for combined subjects)                                                                                                                                                                            
  AA                                                  84 (32.94)           185 (34.84)      1.00                        48 (40.68)    115 (40.93)   1.00                       132 (35.39)   300 (36.95)   1.00               
  AT                                                  122 (47.84)          267 (50.28)      1.00 (0.72-1.40)    0.999   60 (50.85)    127 (45.20)   1.11 (0.70-1.75)   0.670   182 (48.79)   394 (48.52)   1.05 (0.80-1.37)   0.729
  TT                                                  49 (19.22)           79 (14.88)       1.35 (0.87-2.10)    0.181   10 (8.47)     39 (13.88)    0.62 (0.29-1.34)   0.225   59 (15.82)    118 (14.53)   1.14 (0.78-1.65)   0.501
  Additive                                                                                  1.13 (0.91-1.41)    0.256                               0.89 (0.64-1.23)   0.465                               1.06 (0.89-1.27)   0.506
  Dominant                                            171 (67.06)          346 (65.16)      1.08 (0.79-1.48)    0.634   70 (59.32)    166 (59.07)   0.99 (0.64-1.54)   0.968   241 (64.61)   512 (63.05)   1.07 (0.83-1.38)   0.608
  Recessive                                           206 (80.78)          452 (85.12)      1.35 (0.91-2.00)    0.134   108 (91.53)   242 (86.12)   0.59 (0.28-1.22)   0.155   314 (84.18)   694 (85.47)   1.11 (0.79-1.55)   0.560

OR, odds ratio; CI, confidence interval. ^a^ Adjusted for age and gender.

###### 

Stratification analysis for the association between *NEFL* gene polymorphisms and neuroblastoma susceptibility for combined subjects

  Variables         rs11994014 G\>A   rs2979704 T\>C   rs1059111 A\>T                                                                                                 
  ----------------- ----------------- ---------------- ------------------ ------- -------- --------- ------------------ ------- -------- --------- ------------------ -------
  Age, month                                                                                                                                                          
  ≤18               48/120            76/185           1.03 (0.67-1.58)   0.903   48/117   76/188    0.99 (0.64-1.51)   0.947   48/118   76/187    1.00 (0.65-1.53)   0.997
  \>18              82/181            167/326          1.13 (0.82-1.56)   0.451   83/182   166/325   1.12 (0.81-1.54)   0.487   84/182   165/325   1.10 (0.80-1.51)   0.559
  Gender                                                                                                                                                              
  Females           50/135            107/207          1.40 (0.94-2.09)   0.099   50/131   107/211   1.33 (0.89-1.99)   0.161   50/132   107/210   1.35 (0.90-2.01)   0.143
  Males             80/166            136/304          0.93 (0.66-1.30)   0.662   81/168   135/302   0.93 (0.66-1.30)   0.657   82/168   134/302   0.91 (0.65-1.27)   0.574
  Sites of origin                                                                                                                                                     
  Adrenal gland     49/301            85/511           1.02 (0.70-1.49)   0.918   50/299   84/513    0.98 (0.67-1.43)   0.918   50/300   84/512    0.98 (0.67-1.44)   0.933
  Retroperitoneal   24/301            63/511           1.53 (0.93-2.50)   0.092   24/299   63/513    1.52 (0.93-2.48)   0.098   25/300   62/512    1.44 (0.89-2.34)   0.142
  Mediastinum       39/301            70/511           1.07 (0.70-1.62)   0.764   39/299   70/513    1.05 (0.69-1.59)   0.822   39/300   70/512    1.06 (0.70-1.60)   0.797
  Others            14/301            21/511           0.88 (0.44-1.76)   0.719   14/299   21/513    0.87 (0.44-1.74)   0.696   14/300   21/512    0.88 (0.44-1.75)   0.709
  Clinical stages                                                                                                                                                     
  I+II+4s           53/301            111/511          1.25 (0.87-1.78)   0.230   55/299   109/513   1.16 (0.81-1.65)   0.412   55/300   109/512   1.17 (0.82-1.66)   0.392
  III+IV            70/301            119/511          1.01 (0.72-1.40)   0.978   70/299   119/513   1.00 (0.72-1.39)   0.985   70/300   119/512   1.00 (0.72-1.39)   0.998

OR, odds ratio; CI, confidence interval. ^a^ Adjusted for age and gender, omitting the corresponding stratification factor.
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